Gabriel N Hortobagyi

Gabriel N Hortobagyi

UNVERIFIED PROFILE

Are you Gabriel N Hortobagyi?   Register this Author

Register author
Gabriel N Hortobagyi

Gabriel N Hortobagyi

Publications by authors named "Gabriel N Hortobagyi"

Are you Gabriel N Hortobagyi?   Register this Author

100Publications

4092Reads

30Profile Views

Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy.

Cancer Cell 2019 Aug 18;36(2):168-178.e4. Epub 2019 Jul 18.

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung 404, Taiwan; Department of Biotechnology, Asia University, Taichung 413, Taiwan; Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2019.06.008DOI Listing
August 2019

New and important changes in breast cancer TNM: incorporation of biologic factors into staging.

Expert Rev Anticancer Ther 2019 Apr 26;19(4):309-318. Epub 2019 Feb 26.

c Department of Surgery , Cedars-Sinai Medical Center and the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center , Los Angeles , CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2019.1582335DOI Listing
April 2019

Leptomeningeal carcinomatosis in patients with breast cancer.

Crit Rev Oncol Hematol 2019 Mar 1;135:85-94. Epub 2019 Feb 1.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10408428183038
Publisher Site
http://dx.doi.org/10.1016/j.critrevonc.2019.01.020DOI Listing
March 2019

Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.

N Engl J Med 2019 03;380(13):1226-1234

From the Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange (R.S.M.); the SWOG Statistics and Data Management Center (W.E.B., D.L.L.) and Seattle Cancer Care Alliance and University of Washington Medical Center (J.R.G., H.H.L.) - both in Seattle; Loyola University Chicago Stritch School of Medicine, Maywood, IL (K.S.A.); London Health Sciences Centre and the National Cancer Institute of Canada Clinical Trials Group, London, ON, Canada (T.A.V.); the Cancer Center of Kansas and Wichita National Cancer Institute Community Oncology Research Program (NCORP), Wichita (S.R.D.); Kaiser Permanente NCORP, Portland, OR (N.R.T.); the University of Michigan, Ann Arbor (D.F.H.); the University of Arizona Cancer Center, Tucson (R.B.L.); and the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1811714DOI Listing
March 2019

Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells.

Am J Cancer Res 2019 1;9(3):608-618. Epub 2019 Mar 1.

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448061PMC
March 2019

Indirect Evaluation of Bone Saturation with Zoledronic Acid After Long-Term Dosing.

Oncologist 2019 Feb 8;24(2):178-184. Epub 2018 Oct 8.

Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0218DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369945PMC
February 2019

A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β.

Invest New Drugs 2018 12 11;36(6):1103-1109. Epub 2018 Oct 11.

Department of Breast Medical Oncology, Dan L. Duncan Building (CPB5.3542), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-018-0672-z
Publisher Site
http://dx.doi.org/10.1007/s10637-018-0672-zDOI Listing
December 2018

Prognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only Metastases.

Oncologist 2018 Nov 17;23(11):1282-1288. Epub 2018 Aug 17.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0085DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291319PMC
November 2018

Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial.

Breast Cancer Res 2018 10 19;20(1):123. Epub 2018 Oct 19.

Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1050-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194611PMC
October 2018

Three-Year Outcomes With Hypofractionated Versus Conventionally Fractionated Whole-Breast Irradiation: Results of a Randomized, Noninferiority Clinical Trial.

J Clin Oncol 2018 Oct 31:JCO1800317. Epub 2018 Oct 31.

Simona F. Shaitelman, Xiudong Lei, Alastair Thompson, Pamela Schlembach, Elizabeth S. Bloom, Isidora Y. Arzu, Gregory Chronowski, Karen Hoffman, George Perkins, Valerie K. Reed, Shalin J. Shah, Michael C. Stauder, Eric A. Strom, Welela Tereffe, Wendy A. Woodward, Diana N. Amaya, Yu Shen, Gabriel N. Hortobagyi, Kelly K. Hunt, and Benjamin D. Smith, University of Texas MD Anderson Cancer Center, Houston, TX; Daniel Buchholz and Tomas Dvorak, Orlando Health UF Health Cancer Center, Orlando, FL; Emily Grade, Banner MD Anderson Cancer Center, Gilbert AZ; and Thomas A. Buchholz, Scripps MD Anderson Cancer Center, La Jolla, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.00317DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286164PMC
October 2018

American Society of Clinical Oncology's Global Oncology Leadership Task Force: Findings and Actions.

J Glob Oncol 2018 09 11;4:1-8. Epub 2017 Aug 11.

Gabriel N. Hortobagyi, The University of Texas MD Anderson Cancer Center, Houston, TX; Doug Pyle, American Society of Clinical Oncology, Alexandria, VA; Eduardo L. Cazap, Sociedad Latinoamericana y del Caribe de Oncología Médica, Buenos Aires, Argentina; Nagi S. El Saghir, American University of Beirut Medical Center, Beirut, Lebanon; Lawrence N. Shulman, University of Pennsylvania, Philadelphia, PA; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; Lowell E. Schnipper, Beth Israel Deaconess Medical Center, Boston, MA; Clement Adebayo Adebamowo, Institute of Human Virology, Baltimore, MD; David R. Gandara, University of California Davis Comprehensive Cancer Center, Sacramento, CA; Julie Vose, University of Nebraska Medical Center, Omaha, NE; Sandra L. Wong, Dartmouth-Hitchcock Medical Center, Lebanon, NH; and Peter Yu, Hartford HealthCare, Hartford, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JGO.17.00060DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180769PMC
September 2018

CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?

Oncotarget 2018 Sep 28;9(76):34193-34195. Epub 2018 Sep 28.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26134DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188130PMC
September 2018

Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer.

Ann Surg Oncol 2018 Jul 18;25(7):1783-1785. Epub 2018 Apr 18.

Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-018-6486-6DOI Listing
July 2018

Development of CNS metastases and survival in patients with inflammatory breast cancer.

Cancer 2018 06 26;124(11):2299-2305. Epub 2018 Mar 26.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31336DOI Listing
June 2018

New and Important Changes in the TNM Staging System for Breast Cancer.

Am Soc Clin Oncol Educ Book 2018 May;38:457-467

From the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Surgical Oncology and Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY; Department of Surgery, Division of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_201313DOI Listing
May 2018

Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer-Reply.

JAMA Oncol 2018 04;4(4):586

Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2017.3868DOI Listing
April 2018

A phase II study of tipifarnib and gemcitabine in metastatic breast cancer.

Invest New Drugs 2018 04 27;36(2):299-306. Epub 2018 Jan 27.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Dan L. Duncan Building, CPB5.3542, 1515 Holcombe Blvd., Unit 1354, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-018-0564-2
Publisher Site
http://dx.doi.org/10.1007/s10637-018-0564-2DOI Listing
April 2018

Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.

Cancer Cell 2018 02;33(2):187-201.e10

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA; Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA; Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung 404, Taiwan; Department of Biotechnology, Asia University, Taichung 413, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2018.01.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824730PMC
February 2018

Characterization of bone only metastasis patients with respect to tumor subtypes.

NPJ Breast Cancer 2018 25;4. Epub 2018 Jan 25.

3Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41523-018-0054-x
Publisher Site
http://dx.doi.org/10.1038/s41523-018-0054-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785511PMC
January 2018

Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes.

Oncotarget 2017 Sep 31;8(41):70481-70495. Epub 2017 Jul 31.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/19719
Publisher Site
http://dx.doi.org/10.18632/oncotarget.19719DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642571PMC
September 2017

Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

CA Cancer J Clin 2017 07 14;67(4):290-303. Epub 2017 Mar 14.

Professor; Co-Director, Breast Cancer Research Program, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21393DOI Listing
July 2017

Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression.

Breast Cancer Res Treat 2017 Jul 17;164(1):57-67. Epub 2017 Apr 17.

Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-017-4233-5
Publisher Site
http://dx.doi.org/10.1007/s10549-017-4233-5DOI Listing
July 2017

Ultrasound Molecular Imaging: A Good Start.

J Clin Oncol 2017 07 12;35(19):2101-2102. Epub 2017 May 12.

Gary J. Whitman and Gabriel N. Hortobagyi, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.9997DOI Listing
July 2017

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.

J Clin Oncol 2017 Apr 30;35(10):1049-1060. Epub 2017 Jan 30.

W. Fraser Symmans, Caimiao Wei, Rebekah Gould, Xian Yu, Ya Zhang, Maheshwari Ramineni, Kelly Hunt, Thomas A. Buchholz, Vicente Valero, Aman U. Buzdar, Wei Yang, Abenaa M. Brewster, Stacy Moulder, and Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston; Andrew Walls, Uniformed Services University of the Health Sciences, San Antonio, TX; Mei Liu, The General Hospital of People's Liberation Army, Beijing, China; Alex Bousamra, Allegheny General Hospital, Pittsburgh, PA; Bruno Sinn, Charite-Universitatsmedizin, Berlin, Germany; and Lajos Pusztai and Christos Hatzis, Yale University School of Medicine, New Haven, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.1010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455352PMC
April 2017

Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system.

Lancet Oncol 2017 04;18(4):e228-e232

Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30192-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140765PMC
April 2017

Ribociclib for HR-Positive, Advanced Breast Cancer.

N Engl J Med 2017 01;376(3):289

University of Texas M.D. Anderson Cancer Center, Houston, TX

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1615255DOI Listing
January 2017

Deubiquitination and Stabilization of PD-L1 by CSN5.

Cancer Cell 2016 Dec 17;30(6):925-939. Epub 2016 Nov 17.

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA; Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, TX 77030, USA; Center for Molecular Medicine and Graduate Institute of Cancer Biology, China Medical University, Taichung 404, Taiwan; Department of Biotechnology, Asia University, Taichung 413, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.10.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5171205PMC
December 2016

Current challenges of metastatic breast cancer.

Cancer Metastasis Rev 2016 12;35(4):495-514

Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-016-9636-yDOI Listing
December 2016

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

N Engl J Med 2016 11 7;375(18):1738-1748. Epub 2016 Oct 7.

From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1609709DOI Listing
November 2016

Short-term mortality in older patients treated with adjuvant chemotherapy for early-stage breast cancer.

Breast Cancer Res Treat 2016 06 4;157(2):339-350. Epub 2016 May 4.

The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-3815-yDOI Listing
June 2016

AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation.

Cancer Res 2016 Mar 12;76(6):1451-62. Epub 2016 Jan 12.

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Center for Molecular Medicine and Graduate Institute of Cancer Biology, China Medical University, Taichung, Taiwan. Department of Biotechnology, Asia University, Taichung, Taiwan. Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/content/early/2016/01/12/0
Web Search
http://cancerres.aacrjournals.org/content/early/2016/01/12/0
Web Search
http://cancerres.aacrjournals.org/content/early/2016/03/03/0
Web Search
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-15-1941DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794388PMC
March 2016

EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape.

Cancer Res 2016 Mar 12;76(5):1284-96. Epub 2016 Jan 12.

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, Texas. Graduate Institute of Cancer Biology and Center for Molecular Medicine, China Medical, University, Taichung, Taiwan. Department of Biotechnology, Asia University, Taichung, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-2478DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775355PMC
March 2016

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

J Clin Oncol 2016 Feb 26;34(5):419-26. Epub 2015 Oct 26.

Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; David Chen, Tetiana Taran, and David Lebwohl, Novartis Pharmaceuticals, East Hanover, NJ; Martine Piccart and Fabienne Lebrun, Université Libre de Bruxelles, Brussels; Ines Deleu, Oncology Centre, AZ Nikolaas, Sint-Nikolaas, Belgium; Hope S. Rugo, University of California, San Francisco; Ian Anderson, Redwood Regional Oncology Center, Santa Rosa, CA; Howard A. Burris III, Sarah Cannon Research Institute, Nashville, TN; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, Ontario, Canada; Mario Campone, Centre de Recherche en Cancerologie, Nantes-Saint-Herblain; Thomas Bachelot, Centre Léon Bérard, Lyon, France; Shinzaburo Noguchi, Osaka University Medical School; Norikazu Masuda, Osaka National Hospital, Osaka, Japan; Alejandra T. Perez, Memorial Cancer Institute, Hollywood, FL; Mikhail Shtivelband, Ironwood Cancer & Research Centers, Chandler, AZ; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Douglas M. Robinson, Wei He, Abhishek Garg, E. Robert McDonald III, Hans Bitter, and Alan Huang, Novartis Institutes for BioMedical Research, Cambridge, MA; and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.1971DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070556PMC
February 2016

The American Society of Clinical Oncology's Efforts to Support Global Cancer Medicine.

J Clin Oncol 2016 Jan 17;34(1):76-82. Epub 2015 Nov 17.

Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; Nagi S. El-Saghir, American University of Beirut Medical Center, Beirut, Lebanon; Tanja Cufer, University of Ljubljana and University Clinic Golnik, Golnik, Slovenia; Eduardo Cazap, National Cancer Institute of Argentina, Latin American and Caribbean Society of Medical Oncology, Buenos Aires, Argentina; Roselle de Guzman, St Luke's Medical Center, Quezon City, the Philippines; Nicholas Anthony Othieno-Abinya, University of Nairobi, Nairobi, Kenya; Jose Angel Sanchez, Universidad Nacional Autonoma de Honduras, Tegucigalpa, Honduras; and Doug Pyle, American Society of Clinical Oncology, Alexandria, VA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.7696DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320925PMC
January 2016

High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.

Oncologist 2016 Jan 9;21(1):21-7. Epub 2015 Dec 9.

Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0101DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709200PMC
January 2016

Effect of 21-Gene RT-PCR Assay on Adjuvant Therapy and Outcomes in Patients With Stage I Breast Cancer.

Clin Breast Cancer 2015 Dec 18;15(6):458-66. Epub 2015 Jun 18.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2015.06.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644681PMC
December 2015

Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases.

Mol Cancer Ther 2015 Dec 6;14(12):2687-99. Epub 2015 Oct 6.

Section of Translational Breast Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-15-0096DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674309PMC
December 2015

Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis.

Eur J Cancer 2015 Nov 3;51(16):2314-20. Epub 2015 Sep 3.

Department of Medicine, Division of Hematology/Oncology, Mount Sinai Beth Israel, 16th Street and 1st Avenue, New York, NY 10003, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.07.031DOI Listing
November 2015

Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer.

Clin Breast Cancer 2015 Oct 24;15(5):325-31. Epub 2015 Mar 24.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2015.03.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568133PMC
October 2015

Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy.

Breast Cancer Res Treat 2015 Sep 14;153(2):417-23. Epub 2015 Aug 14.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1444, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s10549-015-3533
Web Search
http://link.springer.com/10.1007/s10549-015-3533-x
Publisher Site
http://dx.doi.org/10.1007/s10549-015-3533-xDOI Listing
September 2015

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Authors:
Ayalew Tefferi Hagop Kantarjian S Vincent Rajkumar Lawrence H Baker Jan L Abkowitz John W Adamson Ranjana Hira Advani James Allison Karen H Antman Robert C Bast John M Bennett Edward J Benz Nancy Berliner Joseph Bertino Ravi Bhatia Smita Bhatia Deepa Bhojwani Charles D Blanke Clara D Bloomfield Linda Bosserman Hal E Broxmeyer John C Byrd Fernando Cabanillas George Peter Canellos Bruce A Chabner Asher Chanan-Khan Bruce Cheson Bayard Clarkson Susan L Cohn Gerardo Colon-Otero Jorge Cortes Steven Coutre Massimo Cristofanilli Walter J Curran George Q Daley Daniel J DeAngelo H Joachim Deeg Lawrence H Einhorn Harry P Erba Francisco J Esteva Elihu Estey Isaiah J Fidler James Foran Stephen Forman Emil Freireich Charles Fuchs James N George Morie A Gertz Sergio Giralt Harvey Golomb Peter Greenberg Jordan Gutterman Robert I Handin Samuel Hellman Paulo Marcelo Hoff Ronald Hoffman Waun Ki Hong Mary Horowitz Gabriel N Hortobagyi Clifford Hudis Jean Pierre Issa Bruce Evan Johnson Philip W Kantoff Kenneth Kaushansky David Khayat Fadlo R Khuri Thomas J Kipps Margaret Kripke Robert A Kyle Richard A Larson Theodore S Lawrence Ross Levine Michael P Link Scott M Lippman Sagar Lonial Gary H Lyman Maurie Markman John Mendelsohn Neal J Meropol Yoav Messinger Therese M Mulvey Susan O'Brien Roman Perez-Soler Raphael Pollock Josef Prchal Oliver Press Jerald Radich Kanti Rai Saul A Rosenberg Jacob M Rowe Hope Rugo Carolyn D Runowicz Brenda M Sandmaier Alan Saven Andrew I Schafer Charles Schiffer Mikkael A Sekeres Richard T Silver Lillian L Siu David P Steensma F Marc Stewart Wendy Stock Richard Stone Rainer Storb Louise C Strong Martin S Tallman Michael Thompson Naoto T Ueno Richard A Van Etten Julie M Vose Peter H Wiernik Eric P Winer Anas Younes Andrew D Zelenetz Charles A LeMaistre

Mayo Clin Proc 2015 Aug 23;90(8):996-1000. Epub 2015 Jul 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2015.06.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365030PMC
August 2015

Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers.

Am J Transl Res 2015 15;7(6):1009-20. Epub 2015 Jun 15.

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, Texas 77030 ; Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston Houston, Texas 77030 ; Center for Molecular Medicine, and Graduate Institute of Cancer Biology, China Medical University Taichung 404, Taiwan ; Department of Biotechnology, Asia University Taichung 413, Taiwan.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532735PMC
August 2015

The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.

Int J Oncol 2015 Jul 12;47(1):262-8. Epub 2015 May 12.

Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2015.3003DOI Listing
July 2015

BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing.

Oncologist 2015 Jun 6;20(6):593-7. Epub 2015 May 6.

University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas, USA; University of Texas Health and Science Center at Houston, Houston, Texas, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0425DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571779PMC
June 2015

Reply to F.-C. Bidard et al.

J Clin Oncol 2015 May 13;33(14):1623. Epub 2015 Apr 13.

University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.5519DOI Listing
May 2015

Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes.

Clin Breast Cancer 2015 Apr 2;15(2):153-60. Epub 2014 Oct 2.

Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Department of Systems Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2014.09.006DOI Listing
April 2015

Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer.

Thromb Haemost 2015 Mar 6;113(3):593-8. Epub 2014 Nov 6.

Dr. J. M. Reuben, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA, Tel.: +1 713 745 6837, Fax: +1 713 794 1838, E-mail:

View Article

Download full-text PDF

Source
http://www.thieme-connect.de/DOI/DOI?10.1160/TH14-07-0597
Publisher Site
http://dx.doi.org/10.1160/TH14-07-0597DOI Listing
March 2015

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

N Engl J Med 2015 Mar;372(10):923-32

From the Cleveland Clinic Foundation, Cleveland (H.C.F.M.); SWOG Cancer Research Group Statistical Center, Fred Hutchinson Cancer Research Center (J.M.U., W.E.B.), and Seattle Cancer Care Alliance and University of Washington (J.G.) - all in Seattle; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC (K.-A.P., P.A.F.), Australia and New Zealand Breast Cancer Trials Group (ANZBCTG) (K.-A.P., P.A.F., J.F.F.), Calvary Mater Hospital, Newcastle, NSW (F.B., J.M.L., J.F.F.), and University of Sydney, Sydney (F.B.) - all in Australia; International Breast Cancer Study Group (IBCSG), Bern, Switzerland (K.-A.P., P.A.F.); National Institute of Oncology, Budapest, Hungary (E.H.); Auckland Regional Cancer and Blood Service, Auckland, New Zealand (D.P.); Fox Chase Cancer Center, Philadelphia (L.J.G.); Instituto de Enfermedades Neoplasicas (H.L.G.) and Oncosalud SAC (C.S.V.), Lima, Peru; Dana-Farber Cancer Institute (A.H.P., R.D.G.) and IBCSG Statistical Center (R.D.G.) - both in Boston; Wichita Community Clinical Oncology Program, Wichita (S.R.D.), and University of Kansas, Westwood (C.J.F.) - both in Kansas; University of Southern California Norris Cancer Center, Los Angeles (A.A.G.), the Angeles Clinic and Research Institute, Santa Monica (S.M.), and University of California at Irvine Chao Family Comprehensive Cancer Center, Orange (F.L.M) - all in California; National Cancer Institute, Division of Cancer Prevention, Bethesda, MD (L.M.); M.D. Anderson Cancer Center, Houston (G.N.H.); and Loyola University Medical Center, Cardinal Bernardin Cancer Center, Maywood, IL (K.S.A.).

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/obgynsurvey/2015/06000/Gosereli
Web Search
http://www.nejm.org/doi/abs/10.1056/NEJMoa1413204
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1413204DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405231PMC
March 2015

Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2.

Neoplasia 2015 Mar;17(3):279-88

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neo.2015.01.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372651PMC
March 2015

SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.

J Clin Oncol 2015 Jan 24;33(1):58-64. Epub 2014 Nov 24.

George T. Budd, Halle C. F. Moore, Cleveland Clinic, Cleveland; Timothy D. Moore, Mid Ohio Oncology Hematology, Columbus, OH; William E. Barlow, Danika L. Lew, SWOG Statistical Center; Kristine J. Rinn, Swedish Cancer Institute; Julie R Gralow, Seattle Cancer Care Alliance, Seattle, WA; Timothy J. Hobday Mayo Clinic, Rochester, MN; James A. Stewart, Baystate Medical Center, Springfield, MA; Claudine Isaacs, Georgetown University, Washington, DC; Muhammad Salim, Allan Blair Cancer Centre, Regina, Saskatchewan, Canada; Jonathan K. Cho, University of Hawaii MBCCOP, Honolulu, HI; Kathy S. Albain, Loyola University Chicago, Stritch School of Medicine; Chicago, IL; Helen K. Chew, University of California-Davis, Sacramento, CA; Gary V. Burton, Louisiana State University Health Sciences Center, Shreveport, LA; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing; Lawrence E. Flaherty, Karmanos Cancer Institute/Wayne State University, Detroit, MI; Bradley A. McGregor, Willford Hall Medical Center, Lackland Air Force Base; Gabriel N. Hortobagyi, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert B. Livingston, Arizona Cancer Center, Tucson, AZ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.3296DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268253PMC
January 2015

Outcomes of children exposed in utero to chemotherapy for breast cancer.

Breast Cancer Res 2014 Dec 30;16(6):500. Epub 2014 Dec 30.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 1354, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-014-0500-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303207PMC
December 2014

cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer.

J Cancer 2014 15;5(9):745-53. Epub 2014 Oct 15.

1. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA ; 3. Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.9696DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216798PMC
November 2014

Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.

J Clin Oncol 2014 Oct 2;32(29):3307-29. Epub 2014 Sep 2.

Ann H. Partridge, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center; Beverly Moy, Massachusetts General Hospital, Boston, MA; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria; Michael A. Danso, Virginia Oncology Associates, Norfolk, VA; Lisa A. Carey, University of North Carolina, Chapel Hill, NC; Nancy E. Davidson, University of Pittsburgh Cancer Institute/University of Pittsburgh Medical Center, Pittsburgh, PA; Angelo Di Leo, Sandro Pitigliani Medical Oncology Unit, Prato, Italy; Julie Gralow, University of Washington/Seattle Cancer Care Alliance, Seattle, WA; Gabriel N. Hortobagyi, The University of Texas MD Anderson Cancer Center, Houston, TX; Douglas Yee, University of Minnesota/Masonic Cancer Center, Minneapolis, MN; Shelley B. Brundage, Patient Representative, Washington, DC; Maggie Wilcox, Independent Cancer Patients' Voice; and Ian E. Smith, Royal Marsden Hospital, London, United Kingdom.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2014.56.7479
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.56.7479DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076042PMC
October 2014

Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer.

Cancer Res 2014 Sep 26;74(17):4822-35. Epub 2014 Jun 26.

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas. Graduate Institute for Cancer Biology and Center for Molecular Medicine, China Medical University, Taichung, Taiwan. Department of Biotechnology, Asia University, Taichung, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-0584DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4154991PMC
September 2014

Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer.

Oncologist 2014 Sep 12;19(9):909-14. Epub 2014 Aug 12.

Departments of Breast Medical Oncology, Bioinformatics and Computational Biology, and Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan; Department of Surgery, Division of Breast Surgical Oncology, The Showa University School of Medicine, Tokyo, Japan

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0099DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153464PMC
September 2014

Leptomeningeal disease and breast cancer: the importance of tumor subtype.

Breast Cancer Res Treat 2014 Aug 20;146(3):477-86. Epub 2014 Jul 20.

Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-014-3054-zDOI Listing
August 2014